frontiers | Frontiers in Immunology

TYPE Correction
PUBLISHED 09 January 2024
DOI 10.3389/fimmu.2023.1359973

OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Anette Weyergang
anette.weyergang@rr-research.no

RECEIVED 22 December 2023
ACCEPTED 28 December 2023
PUBLISHED 09 January 2024

CITATION
Longva AS, Berg K and Weyergang A (2024) Corrigendum: Light-enhanced $VEGF_{121}$/rGel induce immunogenic cell death and increase the antitumor activity of αCTLA4 treatment. *Front. Immunol.* 14:1359973. doi: 10.3389/fimmu.2023.1359973

Corrigendum: Light-enhanced $VEGF_{121}$/rGel induce immunogenic cell death and increase the antitumor activity of αCTLA4 treatment

Ane Sager Longva, Kristian Berg and Anette Weyergang*

Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

KEYWORDS

immune check point inhibitor (ICI), photodynamic therapy, photochemical internalization (PCI), vascular targeting, immunogenic cell death (ICD), targeted toxin, vascular endothelial growth factor

A Corrigendum on

Light-enhanced VEGF121/rGel induce immunogenic cell death and increase the antitumor activity of αCTLA4 treatment

By Longva AS, Berg K and Weyergang A (2023) *Front. Immunol.* 14:1278000. doi: 10.3389/fimmu.2023.1278000

In the published article, there was an error in Figure 3 as published. 3C has wrongly also been inserted as 3D resulting in 3C showing the same figure as 3C. The figure legend is correct. The corrected Figure 3 appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

10.3389/fimmu.2023.1359973



FIGURE 3
$VEGF_{121}$/rGel-PCI induces secretion of DAMP signals from CT26 cells. **(A)** Relative cell viability (MTT) 48 hrs post $VEGF_{121}$/rGel-PCI with indicated controls. **(B)** Normalized ATP secretion (bioluminescence assay) 24 and 48 hrs post VEGF/Gel-PCI with indicated controls. **(C, D)** HSP90 and HMGB1 secretion (quantification of western blots) 24 and 48 hrs post $VEGF_{121}$/rGel-PCI with indicated controls. The graphs show averages of 3 independent experiments with error bars indicating SD. Bar labeled with * indicate $p < 0.05$ as compared to non-treated control (NT) (t-test). Significance between two treatments is indicated with * and dotted line (t-test). ** indicate significance with paired t-test. **(E)** Representative western blots of 3 independent experiments of HSP90 and MHGB1 in cell media harvested 24 and 48 hrs post treatment. $VEGF_{121}$/rGel-PCI was performed with the same light dose as used with PDT while PDT_{high} was executed at a higher light dose..